Biotech Values

[genisi]

Regarding Judge Sweet’s decision on the USPTO’s motion for judgment on the pleadings, re Myriad Genetics’ BRCA patents:
Bear in mind that MYGN still has other 'method of use' patents covering the test, which were not invalidated. MYGN will appeal in circuit court and litigation will take few more years. As noted by Peter, Supreme Court ruling in Bilsky case might change the view.